Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline by GBIResearch

VIEWS: 31 PAGES: 172

GBI Research, the leading business intelligence provider, has released its latest research, “Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline” which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

GBI Research also analyzed the promising pipeline molecules that are expected to be launched during the forecast period (2012-2018). The molecules are Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM. The launch of promising molecules is projected to add $2,979m in revenues by 2018. The novel molecules are expected to increase progression free survival, providing a better treatment option to cancer patients. The molecules are expected to address the safety and unmet needs. GBI Research analyzed 63 M&A deals, 95 licensing deals and 67 R&D collaboration agreements that took place during 2007–2011 and found that competitive activity is increasing in the oncology therapeutics market.

More Info
									Novel Therapies in Oncology
Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic
Classes Dominate Late-Stage Pipeline
GBI Research Report Guidance




                                              GBI Research Report Guidance
                                              ·     Section three provides an introduction to the report and details the oncology treatment pathways and
                                                    leading marketed technologies in oncology.
                                              ·     Section four includes analysis of the leading future technologies, such as vaccines and protein kinase
                                                    inhibitors.
                                              ·     Section five includes opportunity and unmet need analysis of the eight main oncology indications:
                                                    breast cancer, colorectal cancer, NHL, NSCLC, prostate cancer, ovarian cancer, cervical cancer and head
                                                    and neck cancer.
                                              ·     Section six provides a detailed product pipeline analysis of the oncology market. It also contains
                                                    detailed analysis of the key therapeutic classes by phase.
                                              ·     Section seven covers the competitive activity in the global oncology market during 2007-2011. This
                                                    section includes analysis of the major M&A deals, licensing deals and co-development deals that have
                                                    recently taken place in the market.




  © GBI Research. This is a licensed product and is not to be photocopied                                                    GBIHC207MR / Published JUL 2012
                                                                                                                                                      Page 2
Executive Summary




                                              Executive Summary
                                              Launch of New Targeted Therapeutics will Drive Market Growth During the Forecast Period 2011-2018
  Cancer treatments are
  becoming increasingly                         Novel Therapies in Oncology, Pipeline by Developmental Phase (%), 2011
  personalized as regulators
  are approving therapeutics                                                                              NDA Filed
                                                                                                                      Phase III
  offering significant benefits                                                            Discovery 4%     1%
                                                                                                                        9%
  to small target populations.

                                                                              Pre-Clinical
                                                                                 23%




                                                                                                                                  Phase II
                                                                                                                                   42%


                                                                                       Phase I
                                                                                        21%

                                                Source: GBI Research, ClinicalTrials.gov




                                              The product pipelines for all therapeutic indications covered in the report have targeted therapeutics in
                                              Phase III; their launch is expected to drive growth in the oncology therapeutics market during the forecast
                                              period 2011-2018.
                                              According to GBI Research findings, cancer treatments are becoming increasingly personalized as regulators
                                              are approving therapeutics offering significant benefits to small target populations. The approval of Pfizer’s
                                              Xalkori (crizotinib), which treats only 5% of the total Non-Small Cell Lung Cancer (NSCLC) patient population,
                                              and the change in Erbitux’s coverage of the colorectal cancer patient population (from every patient to wild
                                              type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) patients) indicates a shift in focus to
                                              more personalized cancer treatment. Although therapeutic options that target a small population are
                                              expensive, their uptake is expected to be rapid in the target population.
                                              A large number of therapeutics in the Phase III pipeline for oncology indications are Monoclonal antibodies.
                                              Monoclonal antibodies such as Avastin (bevacizumab), Erbitux (cetuximab), Rituxan (rituximab) and
                                              Herceptin (trastuzumab) are leading drugs in the oncology therapeutics market. These monoclonal
                                              antibodies are safer and more effective than the conventional chemotherapy treatment options and are
                                              therefore priced at a premium. They target the unmet needs of late-stage cancer patients and are
                                              successful in improving survival and quality of life. The number of monoclonal antibodies in the drug
                                              development pipeline for the treatment of cancer increased over the last decade, driven by their own
                                              success.




  © GBI Research. This is a licensed product and is not to be photocopied                                                            GBIHC207MR / Published JUL 2012
                                                                                                                                                              Page 3
Executive Summary




                                              Novel Therapies to Generate Revenues of $2,979m by 2018 for the Oncology Therapeutics Market
  The launch of novel pipeline
  molecules such as Avastin, T-                 Novel Therapies in Oncology, Novel Therapies Global Revenues ($m), 2012-2018
  DM1, Afinitor, Iniparib,
  Afatinib, V503, Tykerb and                                         3,500
  Thera CIM, is projected to
  add $2,979m in revenues by
  2018                                                               3,000



                                                                     2,500
                                                                             CAGR (2012-2018) -113%
                                                     Revenues ($m)

                                                                     2,000



                                                                     1,500



                                                                     1,000



                                                                      500



                                                                        0
                                                                             2012        2013         2014   2015   2016        2017         2018


                                                Source: GBI Research




                                              The launch of novel pipeline molecules such as Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and
                                              Thera CIM, is projected to add $2,979m in revenues by 2018. The molecules are expected to be launched
                                              during the forecast period from 2012 to 2018. The novel molecules are expected to increase progression-
                                              free survival, therefore providing a better treatment option for cancer patients. The molecules are expected
                                              to address the safety and unmet needs of various cancers such as breast cancer, ovarian cancer, cervical
                                              cancer, NSCLC and Non-Hodgkin’s Lymphoma (NHL).
                                              Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines are the Major Therapeutics Classes in the
                                              Oncology R&D Pipeline
                                              The research and development pipeline consists of 1,198 pipeline molecules. The therapeutic classes under
                                              development are protein kinase inhibitors, monoclonal antibodies and vaccines. The protein kinase inhibitor
                                              has the highest number of molecules under development (250). There are 194 monoclonal antibody
                                              molecules in development and 63 vaccine molecules in the various stages of development. These three
                                              classes constitute 42% of the oncology pipeline.
                                              Protein kinase inhibitors are one of the major classes under development, due to the role of this protein in
                                              helping cancer cells evade normal physiological constraints on growth and survival. Monoclonal antibodies
                                              are also being developed because of their safety and efficacy profiles. They are more effective than
                                              conventional chemotherapy treatment options, target the unmet needs of late-stage cancer patients and
                                              are successful in improving survival and quality of life.




  © GBI Research. This is a licensed product and is not to be photocopied                                                    GBIHC207MR / Published JUL 2012
                                                                                                                                                      Page 4
Table of Contents




                                              1         Table of Contents
                                              1   Table of Contents ........................................................................................................................................ 5
                                                  1.1      List of Tables .................................................................................................................................... 9
                                                  1.2      List of Figures................................................................................................................................. 12
                                              2   Novel Therapies in Oncology - Introduction ............................................................................................. 15
                                              3   Novel Therapies in Oncology - Key Innovations and Technologies ........................................................... 16
                                                  3.1      Introduction................................................................................................................................... 16
                                                      3.1.1      Increase in Cancer ................................................................................................................. 17
                                                      3.1.2      Risk Factors for Cancer .......................................................................................................... 17
                                                  3.2      Oncology Treatment Pathways ..................................................................................................... 17
                                                      3.2.1      Chemotherapeutics ............................................................................................................... 17
                                                      3.2.2      Targeted Therapies ............................................................................................................... 18
                                                  3.3      Leading Marketed Drugs in Oncology ........................................................................................... 18
                                                      3.3.1      Rituxan/ MabThera ............................................................................................................... 18
                                                      3.3.2      Herceptin ............................................................................................................................... 19
                                                      3.3.3      Gleevec/Glivec ....................................................................................................................... 20
                                                      3.3.4      Avastin................................................................................................................................... 21
                                                      3.3.5      Eloxatin.................................................................................................................................. 21
                                                      3.3.6      Erbitux ................................................................................................................................... 22
                                                      3.3.7      Xeloda ................................................................................................................................... 22
                                                      3.3.8      Femara .................................................................................................................................. 23
                                                      3.3.9      Temodar ................................................................................................................................ 23
                                                      3.3.10 Tarceva .................................................................................................................................. 24
                                                      3.3.11 Taxotere ................................................................................................................................ 25
                                                      3.3.12 Revlimid ................................................................................................................................. 25
                                                      3.3.13 Alimta .................................................................................................................................... 26
                                              4   Novel Therapies in Oncology - Leading Novel Drug Classes for the Future............................................... 27
                                                  4.1      Protein Kinase Inhibitors ............................................................................................................... 27
                                                  4.2      Vaccines......................................................................................................................................... 28
                                                      4.2.1      Tumor Cell Vaccines .............................................................................................................. 29
                                                      4.2.2      Antigen Vaccines ................................................................................................................... 29
                                                      4.2.3      Dendritic Cell Vaccines .......................................................................................................... 30
                                                      4.2.4      Anti-Idiotype vaccines ........................................................................................................... 30
                                              5   Novel Therapies in Oncology - Opportunity and Unmet Need Analysis .................................................... 31
                                                  5.1      Breast Cancer ................................................................................................................................ 31
                                                  5.2      Colorectal Cancer .......................................................................................................................... 33
                                                  5.3      NHL ................................................................................................................................................ 34
                                                  5.4      NSCLC ............................................................................................................................................ 36
                                                  5.5      Prostate Cancer ............................................................................................................................. 38
                                                  5.6      Ovarian Cancer .............................................................................................................................. 39
                                                  5.7      Cervical Cancer .............................................................................................................................. 40
                                                  5.8      Head and Neck Cancer .................................................................................................................. 41
                                              6   Novel Therapies in Oncology - Product Pipeline Analysis ......................................................................... 43
                                                  6.1      Introduction................................................................................................................................... 43
                                                  6.2      Breast Cancer ................................................................................................................................ 47
                                                      6.2.1      Breast Cancer Pipeline - Introduction .................................................................................... 47
                                                      6.2.2      Breast Cancer Pipeline - Analysis by Therapeutic Class ......................................................... 48
                                                      6.2.3      Breast Cancer Pipeline - Pre-Clinical ...................................................................................... 53
                                                      6.2.4      Breast Cancer Pipeline - Discovery ........................................................................................ 54
                                                      6.2.5      Breast Cancer Pipeline - Phase I ............................................................................................ 55
                                                      6.2.6      Breast Cancer Pipeline - Phase II ........................................................................................... 57


  © GBI Research. This is a licensed product and is not to be photocopied                                                                                            GBIHC207MR / Published JUL 2012
                                                                                                                                                                                              Page 5
Table of Contents




                                                      6.2.7     Breast Cancer Pipeline - Phase III .......................................................................................... 61
                                                      6.2.8     Breast Cancer Pipeline - NDA Filed ........................................................................................ 61
                                                  6.3      Colorectal Cancer .......................................................................................................................... 62
                                                      6.3.1     Colorectal Cancer Pipeline - Introduction .............................................................................. 62
                                                      6.3.2     Colorectal Cancer Pipeline - Analysis by Therapeutic Class ................................................... 63
                                                      6.3.3     Colorectal Cancer Pipeline - Pre-Clinical ................................................................................ 68
                                                      6.3.4     Colorectal Cancer Pipeline - Discovery................................................................................... 68
                                                      6.3.5     Colorectal Cancer Pipeline - Phase I ...................................................................................... 69
                                                      6.3.6     Colorectal Cancer Pipeline - Phase II ..................................................................................... 71
                                                      6.3.7     Colorectal Cancer Pipeline - Phase III .................................................................................... 74
                                                  6.4      NHL ................................................................................................................................................ 75
                                                      6.4.1     NHL Pipeline - Introduction.................................................................................................... 75
                                                      6.4.2     NHL Pipeline - Analysis by Therapeutic Class ......................................................................... 76
                                                      6.4.3     NHL Pipeline - Pre-Clinical ..................................................................................................... 81
                                                      6.4.4     NHL Pipeline - Discovery ........................................................................................................ 81
                                                      6.4.5     NHL Pipeline - Phase I ............................................................................................................ 82
                                                      6.4.6     NHL Pipeline - Phase II ........................................................................................................... 84
                                                      6.4.7     NHL Pipeline - Phase III .......................................................................................................... 85
                                                      6.4.8     NHL Pipeline - NDA Filed........................................................................................................ 85
                                                  6.5      NSCLC ............................................................................................................................................ 86
                                                      6.5.1     NSCLC Pipeline - Introduction ................................................................................................ 86
                                                      6.5.2     NSCLC Pipeline - Analysis by Therapeutic Class ..................................................................... 87
                                                      6.5.3     NSCLC Pipeline - Pre-Clinical .................................................................................................. 93
                                                      6.5.4     NSCLC Pipeline - Discovery .................................................................................................... 94
                                                      6.5.5     NSCLC Pipeline - Phase I ........................................................................................................ 94
                                                      6.5.6     NSCLC Pipeline - Phase II ....................................................................................................... 95
                                                      6.5.7     NSCLC Pipeline - Phase III ...................................................................................................... 97
                                                      6.5.8     NSCLC Pipeline - NDA Filed .................................................................................................... 98
                                                  6.6      Prostate Cancer ............................................................................................................................. 99
                                                      6.6.1     Prostate Cancer Pipeline - Introduction ................................................................................. 99
                                                      6.6.2     Prostate Cancer Pipeline - Analysis by Therapeutic Class .................................................... 100
                                                      6.6.3     Prostate Cancer Pipeline - Pre-Clinical................................................................................. 106
                                                      6.6.4     Prostate Cancer Pipeline - Discovery ................................................................................... 107
                                                      6.6.5     Prostate Cancer Pipeline - Phase I ....................................................................................... 108
                                                      6.6.6     Prostate Cancer Pipeline - Phase II ...................................................................................... 109
                                                      6.6.7     Prostate Cancer Pipeline - Phase III ..................................................................................... 111
                                                      6.6.8     Prostate Cancer Pipeline - NDA Filed ................................................................................... 112
                                                  6.7      Ovarian Cancer ............................................................................................................................ 112
                                                      6.7.1     Ovarian Cancer Pipeline - Introduction ................................................................................ 112
                                                      6.7.2     Ovarian Cancer Pipeline - Analysis by Therapeutic Class ..................................................... 113
                                                      6.7.3     Ovarian Cancer Pipeline - Pre-Clinical ................................................................................. 117
                                                      6.7.4     Ovarian Cancer Pipeline - Discovery .................................................................................... 118
                                                      6.7.5     Ovarian Cancer Pipeline - Phase I ........................................................................................ 119
                                                      6.7.6     Ovarian Cancer Pipeline - Phase II ....................................................................................... 120
                                                      6.7.7     Ovarian Cancer Pipeline - Phase III ...................................................................................... 122
                                                      6.7.8     Ovarian Cancer Pipeline - NDA Filed.................................................................................... 122
                                                  6.8      Cervical Cancer ............................................................................................................................ 123
                                                      6.8.1     Cervical Cancer Pipeline - Introduction ................................................................................ 123
                                                      6.8.2     Cervical Cancer Pipeline - Analysis by Therapeutic Class ..................................................... 124
                                                      6.8.3     Cervical Cancer Pipeline - Pre-Clinical.................................................................................. 128
                                                      6.8.4     Cervical Cancer Pipeline - Phase I ........................................................................................ 128
                                                      6.8.5     Cervical Cancer Pipeline - Phase II ....................................................................................... 129


  © GBI Research. This is a licensed product and is not to be photocopied                                                                                            GBIHC207MR / Published JUL 2012
                                                                                                                                                                                              Page 6
Table of Contents




                                                    6.8.6      Cervical Cancer Pipeline - Phase III ...................................................................................... 129
                                                  6.9    Head and Neck Cancer ................................................................................................................ 130
                                                    6.9.1      Head and Neck Cancer Pipeline - Introduction .................................................................... 130
                                                    6.9.2      Head and Neck Cancer Pipeline - Analysis by Therapeutic Class ......................................... 131
                                                    6.9.3      Head and Neck Cancer Pipeline - Pre-Clinical ...................................................................... 135
                                                    6.9.4      Head and Neck Cancer Pipeline - Discovery......................................................................... 135
                                                    6.9.5      Head and Neck Cancer Pipeline - Phase I ............................................................................ 136
                                                    6.9.6      Head and Neck Cancer Pipeline - Phase II ........................................................................... 137
                                                    6.9.7      Head and Neck Cancer Pipeline - Phase III .......................................................................... 139
                                              7 Novel Therapies In Oncology - Promising Molecules .............................................................................. 140
                                                7.1      T-DM1.......................................................................................................................................... 140
                                                    7.1.1      Introduction ......................................................................................................................... 140
                                                    7.1.2      Mechanism of Action ........................................................................................................... 140
                                                    7.1.3      Revenues ............................................................................................................................. 140
                                                7.2      Afinitor (everolimus) ................................................................................................................... 141
                                                    7.2.1      Introduction ......................................................................................................................... 141
                                                    7.2.2      Mechanism of Action ........................................................................................................... 141
                                                    7.2.3      Revenues ............................................................................................................................. 142
                                                7.3      Iniparib (E75) ............................................................................................................................... 143
                                                    7.3.1      Introduction ......................................................................................................................... 143
                                                    7.3.2      Mechanism of Action ........................................................................................................... 143
                                                    7.3.3      Revenues ............................................................................................................................. 144
                                                7.4      Afatinib ........................................................................................................................................ 145
                                                    7.4.1      Introduction ......................................................................................................................... 145
                                                    7.4.2      Mechanism of Action ........................................................................................................... 145
                                                    7.4.3      Revenues ............................................................................................................................. 145
                                                7.5      Avastin ......................................................................................................................................... 146
                                                    7.5.1      Introduction ......................................................................................................................... 146
                                                    7.5.2      Mechanism of Action ........................................................................................................... 146
                                                    7.5.3      Revenues ............................................................................................................................. 146
                                                7.6      Farletuzumab .............................................................................................................................. 147
                                                    7.6.1      Introduction ......................................................................................................................... 147
                                                    7.6.2      Mechanism of Action ........................................................................................................... 147
                                                    7.6.3      Revenues ............................................................................................................................. 148
                                                7.7      V503 ............................................................................................................................................ 149
                                                    7.7.1      Introduction ......................................................................................................................... 149
                                                    7.7.2      Mechanism of Action ........................................................................................................... 149
                                                    7.7.3      Revenues ............................................................................................................................. 149
                                                7.8      Tykerb .......................................................................................................................................... 150
                                                    7.8.1      Introduction ......................................................................................................................... 150
                                                    7.8.2      Mechanism of Action ........................................................................................................... 150
                                                    7.8.3      Revenues ............................................................................................................................. 151
                                                7.9      TheraCIM ..................................................................................................................................... 152
                                                    7.9.1      Introduction ......................................................................................................................... 152
                                                    7.9.2      Mechanism of Action ........................................................................................................... 152
                                                    7.9.3      Revenues ............................................................................................................................. 153
                                              8 Novel Therapies In Oncology - Strategic Consolidations ......................................................................... 154
                                                8.1      M&A Landscape .......................................................................................................................... 154
                                                    8.1.1      M&A Deals by Year.............................................................................................................. 156
                                                    8.1.2      M&A Deals by Geography ................................................................................................... 157
                                                    8.1.3      M&A Deals by Value............................................................................................................ 158
                                                    8.1.4      M&A Deals by Deal Type ..................................................................................................... 159


  © GBI Research. This is a licensed product and is not to be photocopied                                                                                         GBIHC207MR / Published JUL 2012
                                                                                                                                                                                           Page 7
Table of Contents




                                                  8.2    R&D Licensing Agreements ......................................................................................................... 160
                                                    8.2.1     Deals by Year ....................................................................................................................... 161
                                                    8.2.2     Deals by Geography ............................................................................................................ 162
                                                    8.2.3     Deals by Value ..................................................................................................................... 163
                                                8.3      Co-Development Agreements ..................................................................................................... 164
                                                    8.3.1     Deals by Year ....................................................................................................................... 165
                                                    8.3.2     Deals by Geography ............................................................................................................ 166
                                                    8.3.3     Deals by Value ..................................................................................................................... 167
                                              9 Novel Therapies In Oncology - Appendix ................................................................................................ 168
                                                9.1      Market Definitions....................................................................................................................... 168
                                                9.2      Abbreviations .............................................................................................................................. 168
                                                9.3      Sources ........................................................................................................................................ 169
                                                9.4      Research Methodology ............................................................................................................... 170
                                                    9.4.1     Coverage ............................................................................................................................. 170
                                                    9.4.2     Secondary Research ............................................................................................................ 170
                                                    9.4.3     Primary Research ................................................................................................................ 171
                                                    9.4.4     Section Wise Methodology .................................................................................................. 171
                                                    9.4.5     Expert Panel Validation ....................................................................................................... 171
                                                9.5      Contact Us ................................................................................................................................... 172
                                                9.6      Disclaimer .................................................................................................................................... 172




  © GBI Research. This is a licensed product and is not to be photocopied                                                                                         GBIHC207MR / Published JUL 2012
                                                                                                                                                                                           Page 8
Table of Contents




                                              1.1      List of Tables
                                              Table 1:     Novel Therapies in Oncology, Oncology Clinical Trials, 2011 ....................................................... 16
                                              Table 2:     Novel Therapies in Oncology, Pipeline by Developmental Phase, 2011 ....................................... 43
                                              Table 3:     Novel Therapies in Oncology, Pipeline by Indication, 2011 .......................................................... 45
                                              Table 4:     Novel Therapies in Oncology, Pipeline by Therapeutic Class, 2011.............................................. 46
                                              Table 5:     Novel Therapies in Oncology, Breast Cancer Pipeline by Phase, 2011 ......................................... 47
                                              Table 6:     Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................... 48
                                              Table 7:     Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class,
                                                           2011.............................................................................................................................................. 49
                                              Table 8:     Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class,
                                                           2011.............................................................................................................................................. 50
                                              Table 9:     Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class,
                                                           2011.............................................................................................................................................. 51
                                              Table 10:    Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class,
                                                           2011.............................................................................................................................................. 52
                                              Table 11:    Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 ......... 53
                                              Table 12:    Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Stage Molecules, 2011 ............ 54
                                              Table 13:    Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules, 2011.......................... 55
                                              Table 14:    Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules, 2011......................... 57
                                              Table 15:    Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules, 2011........................ 61
                                              Table 16:    Novel Therapies in Oncology, Breast Cancer Pipeline, NDA Filed Molecules, 2011 ..................... 61
                                              Table 17:    Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase, 2011 ................................... 62
                                              Table 18:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................... 63
                                              Table 19:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................... 64
                                              Table 20:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class
                                                           , 2011 ............................................................................................................................................ 65
                                              Table 21:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................... 66
                                              Table 22:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................... 67
                                              Table 23:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 ... 68
                                              Table 24:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Stage Molecules, 2011 ...... 68
                                              Table 25:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules, 2011.................... 69
                                              Table 26:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules, 2011................... 71
                                              Table 27:    Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules, 2011.................. 74
                                              Table 28:    Novel Therapies in Oncology, NHL Pipeline by Phase, 2011......................................................... 75
                                              Table 29:    Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 . 76
                                              Table 30:    Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class, 2011 ... 77
                                              Table 31:    Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class, 2011 ....... 78
                                              Table 32:    Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class, 2011 ...... 79
                                              Table 33:    Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class, 2011 ..... 80
                                              Table 34:    Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Stage Molecules, 2011 ......................... 81
                                              Table 35:    Novel Therapies in Oncology, NHL Pipeline, Discovery Stage Molecules, 2011 ........................... 81
                                              Table 36:    Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules, 2011 ......................................... 82
                                              Table 37:    Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules, 2011 ........................................ 84
                                              Table 38:    Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules, 2011 ....................................... 85
                                              Table 39:    Novel Therapies in Oncology, NHL Pipeline, NDA Filed Molecules, 2011 ..................................... 85
                                              Table 40:    Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase, 2011 .................................... 86
                                              Table 41:    Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
                                                           ...................................................................................................................................................... 87
                                              Table 42:    Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class, 2011 88
                                              Table 43:    Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class, 2011 .... 89
                                              Table 44:    Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class, 2011 ... 90
                                              Table 45:    Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class, 2011 .. 91
                                              Table 46:    Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class, 2011 92


  © GBI Research. This is a licensed product and is not to be photocopied                                                                                            GBIHC207MR / Published JUL 2012
                                                                                                                                                                                              Page 9
Table of Contents




                                              Table 47:    Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Stage Molecules, 2011 ..................... 93
                                              Table 48:    Novel Therapies in Oncology, NSCLC Pipeline, Discovery Stage Molecules, 2011 ........................ 94
                                              Table 49:    Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules, 2011...................................... 94
                                              Table 50:    Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules, 2011..................................... 95
                                              Table 51:    Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules, 2011.................................... 97
                                              Table 52:    Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules, 2011 ................................. 98
                                              Table 53:    Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase, 2011 .................... 99
                                              Table 54:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................. 101
                                              Table 55:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 102
                                              Table 56:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 103
                                              Table 57:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 104
                                              Table 58:    Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................. 105
                                              Table 59:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 .... 106
                                              Table 60:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Discovery Stage Molecules, 2011 ...... 107
                                              Table 61:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules, 2011 .................... 108
                                              Table 62:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules, 2011 ................... 109
                                              Table 63:    Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules, 2011 .................. 111
                                              Table 64:    Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules, 2011 ................ 112
                                              Table 65:    Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase, 2011 ................... 112
                                              Table 66:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................. 113
                                              Table 67:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic
                                                           Class,2011 ................................................................................................................................... 114
                                              Table 68:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 115
                                              Table 69:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 116
                                              Table 70:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 ..... 117
                                              Table 71:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Discovery Stage Molecules, 2011 ....... 118
                                              Table 72:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules, 2011 ..................... 119
                                              Table 73:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules, 2011 .................... 120
                                              Table 74:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 ................... 122
                                              Table 75:    Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 ................... 122
                                              Table 76:    Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase, 2011 ................... 123
                                              Table 77:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................. 124
                                              Table 78:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 125
                                              Table 79:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 126
                                              Table 80:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class,
                                                           2011............................................................................................................................................ 127
                                              Table 81:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 ..... 128
                                              Table 82:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules, 2011 ..................... 128
                                              Table 83:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules, 2011 .................... 129
                                              Table 84:    Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules, 2011 ................... 129
                                              Table 85:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase, 2011 ........ 130
                                              Table 86:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by
                                                           Therapeutic Class, 2011 .............................................................................................................. 131
                                              Table 87:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Molecules by
                                                           Therapeutic Class, 2011 .............................................................................................................. 131
                                              Table 88:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................. 132



  © GBI Research. This is a licensed product and is not to be photocopied                                                                                         GBIHC207MR / Published JUL 2012
                                                                                                                                                                                          Page 10
Table of Contents




                                              Table 89:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic
                                                           Class, 2011 .................................................................................................................................. 133
                                              Table 90:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by
                                                           Therapeutic Class, 2011 .............................................................................................................. 134
                                              Table 91:    Novel Therapies in Oncology, Head And Neck Cancer Pipeline, Pre-Clinical Stage Molecules, 2011
                                                           .................................................................................................................................................... 135
                                              Table 92:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Stage Molecules, 2011
                                                           .................................................................................................................................................... 135
                                              Table 93:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules, 2011.......... 136
                                              Table 94:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules, 2011......... 137
                                              Table 95:    Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules, 2011........ 139
                                              Table 96:    Novel Therapies in Oncology, T-DM
								
To top